Current status and patent prospective of lipid nanoparticle for mRNA delivery

IntroductionMessenger RNA-lipid nanoparticle (mRNA-LNP) delivery is currently a research hotspot in pharmaceutics. LNP has emerged in pharmaceutical industry as popular and effective vehicle for mRNA delivery. It is therefore significant to understand current landscape and recent development of LNP for mRNA delivery.Areas coveredThis article provides patent landscape and recent development for mRNA-LNP delivery by US-granted patent analysis. The US-granted patents from January 2003 to December 2022 were retrieved and analyzed by using PatSnap.Expert opinionGlobally, the present article was the first one which showed that mRNA-LNP delivery system demonstrated three therapeutic applications including vaccines, anticancer, and diseases associated with protein or enzyme deficiencies. ModernaTX is the most powerful company and leads almost all technologies in mRNA-LNP field. In addition, the technologies related to LNP for mRNA delivery are virtually controlled by top three assignees. mRNA-LNP delivery in therapy of diseases associated with enzyme deficiencies may be a future trend. The article provides recent advances in LNP for mRNA delivery.